Drug intelligence / Profile preview

cannabinol

Development stage: Phase 3
Lead developer: InMed Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Inhalation, Sublingual, Topical, Transdermal

Overview

Cannabinol (CBN) is a mildly psychoactive phytocannabinoid found in the Cannabis sativa plant. It was the first cannabinoid to be isolated from cannabis and was discovered in 1896. CBN acts as a low-affinity partial agonist at both CB1 and CB2 receptors of the endocannabinoid system, but with much lower potency than delta-9-tetrahydrocannabinol (THC). This means that higher doses are required to produce noticeable effects, which may include mild sedation. Research on CBN is limited; early studies suggest it may affect the immune system and reduce pain, with interest in its use for sleep disorders, pain management, and appetite stimulation[1][3].

Brand names: TruCBN
Other names: cannabinolCBN

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on cannabinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabinol.

Explore the full profile